Nicox: NCX 470 application accepted for review in China
The ophthalmology laboratory based in Biot specified that the application was filed in August 2026 by Ocumension Therapeutics, its exclusive licensee in China. Nicox will receive tiered royalties of 6% to 12% on NCX 470 sales realized by Ocumension.
Nicox announced on September 11, 2026 the acceptance for review in China of the marketing authorization application (NDA) for its eye drop NCX 470. This acceptance marks the opening, by the Chinese regulatory authority, of the review phase of the file devoted to this candidate treatment. Dated September 10, 2026, it concerns the use of NCX 470 to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
A Chinese decision expected after the FDA's
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
According to Nicox, the examination of a drug in China generally takes 12 to 18 months after file submission, and the decision on NCX 470 is expected there after that of the FDA. In the United States, Nicox announced on August 27, 2026 the acceptance of the file by the FDA, which set April 30, 2027 as the target date for its decision. Ocumension, which is among the main shareholders of Nicox, paid it 18 million euros in license fees for China, Korea and Southeast Asia, and financed 50% of the costs of the Denali clinical trial.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: FY2024
Key reported figures
Revenue: 7,9 millions d'euros
Revenue growth: 14,5 %
Net income: -22,4 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
